RICHMOND, VA / ACCESSWIRE / February 8, 2017 / Exactus, Inc. (OTCQB: EXDI), a life science company that is developing and planning to commercialize ultra-fast, handheld, point-of-care (POC) diagnostic tools powering informed patient management, announced today that Company management will present at the BIO CEO & Investor Conference on Tuesday, February 14, 2017 at 8:30 AM Eastern Standard Time. The conference will take place February 13-14, 2017 at the Waldorf Astoria, New York, New York.
Exactus CEO, Philip Young will deliver the Company’s corporate presentation and discuss recent business highlights. Management will also be available for one-on-one meetings. To arrange a meeting with management, please contact Tim Ryan at try[email protected] or Robert Haag at [email protected].
About the BIO CEO & Investor Conference
Now in its 19th year, the BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies. Because its mission is to support industry-wide success, the BIO CEO & Investor Conference presents a broad and unbiased view of investment opportunities.
Each year the BIO CEO & Investor Conference provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry.
The conference features issue-oriented plenary sessions, educational sessions focused on hot therapeutic areas and key business issues, company presentations, one-on-one meetings, and networking opportunities.
BIO CEO & Investor Conference therapeutic workshops feature MDs, CSOs and industry analysts discussing the latest information on pipeline innovation for breakthrough therapeutic topics in biopharma. Seasoned industry executives and analysts delve into timely and relevant business models, deal-making and investment trends on our business roundtables.
About Exactus Inc.
Exactus is a publicly traded life science company based in Richmond, Virginia that is developing and planning to commercialize point-of-care (POC) diagnostics for measuring proteolytic enzymes in the blood. We anticipate our lead product, the FibriLyzer™, will provide a simple and cost effective means to assess the fibrinolytic status of patients in a broad range of applications and that the use of the FibriLyzer™ could provide the basis for improved management of patients who are at-risk of hemorrhage, speeding treatment decisions and potentially improving patient outcomes and possibly improving health economics.
Our second product candidate, the MatriLyzer™, may be used to detect the recurrence of cancer, and can be used as an at-home monitoring device or during routine office visits. The appearance of elevated levels of collagenase, the enzyme that degrades collagen, have been identified as an early hallmark of cancer recurrence and metastasis. The MatriLyzer™ can communicate directly with the attending oncologist via a smart phone application to ensure that (i) the tests are being used properly and (ii) when collagenase levels are elevated signaling the need for the patient to have a more thorough examination. For more information about Exactus, please visit our website at: www.exactusinc.com.
This press release and any statements of representatives and partners of Exactus, Inc. (the “Company”) related thereto contain, or may contain, among other things, certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company’s plans, objectives, projections, expectations and intentions and other statements identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential” or similar expressions. These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties, including those detailed in the Company’s filings with the Securities and Exchange Commission. Actual results (including, without limitation, the actual timing for, or actual results of, the Company’s clinical trial described herein or the FDA’s review of such results) may differ significantly from those set forth or implied in the forward-looking statements. These forward-looking statements involve numerous risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company’s control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
For more information:
Philip J. Young, President and CEO
Tim Ryan, EVP
Investor Relations Contact:
Tel: (866) 976-4784